tbuckley/cabot-search huggingface dataset:
Abstract 10775: Dressler’s Syndrome Following Catheter Ablation of Atrial Fibrillation: A Case Series
Authors: Domenico G Della Rocca, Luigi Di Biase, Sanghamitra Mohanty, Chintan G Trivedi, Nicola Tarantino, Jorge Romero, Bryan MacDonald, Carola Gianni, Amin Al-Ahmad, Mohammed Bassiouny, Veronica Natale, J D Burkhardt, G J Gallinghouse, Rodney P Horton, Javier Sanchez, Andrea Natale
Journal: Circulation (2019)

Introduction: Dressler’s syndrome is a secondary form of pleuro-pericarditis caused by an immune system response to heart damage. The onset of Dressler’s syndrome following catheter ablation (CA) h...
Severe Sepsis As Immune Stimulation and Protection from Relapse of Childhood Acute Lymphoblastic Leukemia (ALL): Results from a Pilot Study and Validation of Events in a National Administrative Dataset
Authors: Alix E. Seif, Viviane C. Cahen, Yimei Li, Caitlin Walfoort Elgarten, Amanda M. Dinofia, Jennifer J. Wilkes, Lena Winestone, Yuan-Shung V. Huang, Julie C Fitzgerald, Brian T Fisher, Gregor S.D. Reid, Kelly D Getz, Richard Aplenc
Journal: Blood (2017)
Abstract LB057: Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST)
Authors: Niamh Coleman, Charles Abbot, Neeta Somaiah, Sarina Piha-Paul, Shubham Pant, Jordi Rodon, S. Greg Call, Sean Boyle, Funda Meric-Bernstam, Filip Janku
Journal: Cancer Research (2021)

Abstract Background: The discovery of oncogenic mutations as potential targets for cancer therapy has revolutionized the treatment of GIST and other cancers. However, adaptive resistance ultimately develops in nearly all patients, which emphasizes the need for a more detailed understanding of the underlying molecular profile. Methods: Using the Personalis ImmunoID NeXT Platform® (Personalis, Inc.; Menlo Park, CA), an augmented exome/transcriptome platform and analysis pipeline, we performed whole exome sequencing (WES) and whole transcriptome total RNA sequencing (RNA-Seq) of paired baseline tumor and normal tissue. NeXT Liquid Biopsy™ (Personalis, Inc.) was used for WES of plasma-derived ctDNA from serially collected samples collected at baseline, after 1 month and at progression to experimental systemic therapies in 15 patients with advanced/metastatic GIST. Results: WES of tumor tissue samples from all 15 patients confirmed underlying KIT mutation in all patients. There was large heterogeneity of other molecular alterations, which included therapeutically relevant molecular alterations, such as microsatellite instability-high (MSI-high) in 1 sample. RNA-Seq of tumor tissue revealed recurrent overexpression of GALR2, NY-ESO-1 and other genes involved in cancer progression, angiogenesis and anticancer immunity. Patients with response to systemic therapies demonstrated lower levels of cytolytic activity measured by CYT score in tumor tissue compared to patients without response (P=0.04). KIT mutations were detected in serially collected ctDNA samples from 12 (80%) of 15 patients. Quantity of KIT and other mutant ctDNA dynamically tracked the clonal evolution and clinical course during systemic therapy. Conclusions: Comprehensive genomic profiling (WES and RNA-Seq) of tumor tissue and WES of serially collected ctDNA is feasible and detects underlying druggable KIT mutations and other molecular alterations. Citation Format: Niamh Coleman, Charles Abbot, Neeta Somaiah, Sarina Piha-Paul, Shubham Pant, Jordi Rodon, S. Greg Call, Sean Boyle, Funda Meric-Bernstam, Filip Janku. Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB057.
Impact of testicular torsion on fertility and erectile dysfunction: A multicenter national retrospective studyTORSAFUF
Authors: W. Berchiche, M. Sbizzera, F. Lannes, U. Pinar, I. Duquesne, M. Felber, C. Plassais, V.T. Dang, N. Ali Benali, C. Gaillard, A. Mauger De Varennes, G. Margue, F. Bardet, M. Hulin, A. Manuguerra, W. Wandoren, M. Chabennes, V. Gaillard, X. Matillon, Z.E. Khene, B. Pradere
Journal: European Urology (2021)
FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
Authors: Bethan L. Clifford, Leslie R. Sedgeman, Kevin J. Williams, Pauline Morand, Angela Cheng, Kelsey E. Jarrett, Alvin P. Chan, Madelaine C. Brearley-Sholto, Annika Wahlström, Julianne W. Ashby, William Barshop, James Wohlschlegel, Anna C. Calkin, Yingying Liu, Anders Thorell, Peter J. Meikle, Brian G. Drew, Julia J. Mack, Hanns-Ulrich Marschall, Elizabeth J. Tarling, Peter A. Edwards, Thomas Q. de Aguiar Vallim
Journal: Cell Metabolism (2021)
Abstract 1578: Heating it up: Targeting RAS/RAF/PI3K pathway to make melanoma tumors ‘immunologically hot' and suitable for checkpoint blockade immunotherapies
Authors: Chi Yan, Nabil Saleh, Caroline Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas B. Johnson, Rebecca L. Shattuck-Brandt, Sheau-Chiann Chen, Gregory D. Ayers, Ann Richmond
Journal: Cancer Research (2021)

Abstract Immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma. However, ICB fails in many patients and has dangerous side effects. Rigosertib (RGS), a non-ATP-competitive small molecule RAS mimetic, has the potential to block oncogenic RAS-RAF-MEK-ERK and/or PI3K-AKT-mTOR signaling pathways. Using immunocompetent mouse models of B16F10 (BRAFwt) and YUMM3.3 (BRAFmut) melanoma, we identified that RGS treatment (300mg/kg) of melanoma tumor-bearing mice is well tolerated and results in ~50% inhibition of tumor growth as monotherapy and ~70% inhibition in synergy with αPD1+αCTLA4. RGS-induced tumor inhibition depends on the induction of CD40 expression on melanoma cells, followed by immunogenic cell death, leading to an inflamed tumor microenvironment with enrichment of dendritic cells and activated CD8+ Tc cells. The RGS-initiated suppression of tumor growth was partially reversed by either suppression of CD40 expression in the melanoma cells by shRNA, or depletion of CD8+ Tc cells. Analysis of multiple published patient melanoma studies confirms that a high CD40 expression level correlates with CD80, ICOS-L, beneficial type-I T-cell responses, and better survival in melanoma patients. The CD40 levels in melanoma cells are prognostic for therapeutic response to RGS, RAF inhibitor and ICB. Notably, multiplex IHC analysis showed that BRAF inhibitor treatment significantly induces CD40+SOX10+ melanoma cells in the tumors of melanoma patients and patient-derived xenografts. Our preclinical data support the therapeutic use of RGS plus αPD1+αCTLA4 in RAS/RAF/MEK and/or PI3K pathway-activated melanoma tumors and point to the need for clinical trials to determine the clinical benefit of RGS plus ICB for metastatic melanoma patients who do not respond to ICB alone. The authors sincerely thank Onconova Therapeutics, Newtown, PA 18940 for kindly supplying Rigosertib for this work. Citation Format: Chi Yan, Nabil Saleh, Caroline Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas B. Johnson, Rebecca L. Shattuck-Brandt, Sheau-Chiann Chen, Gregory D. Ayers, Ann Richmond. Heating it up: Targeting RAS/RAF/PI3K pathway to make melanoma tumors ‘immunologically hot' and suitable for checkpoint blockade immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1578.
Open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: 30-day and 90-day complication rates comparison from a single centre randomised controlled trial
Authors: R. Mastroianni, G. Tuderti, U. Anceschi, A.M. Bove, A. Brassetti, M. Ferriero, L. Misuraca, S. Guaglianone, M. Gallucci, G. Simone
Journal: European Urology (2021)
Novel “endoloop and hemoclips” technique for mucosal prolapse causing efferent loop syndrome
Authors: Manoj A. Vyawahare, Ramakant Tayade
Journal: Endoscopy (2021)

Efferent loop syndrome (ELS) is defined as mechanical obstruction of the efferent jejunal limb after gastric surgery and is less common than afferent loop syndrome [1]. Adhesive band, kinking, internal herniation, intussusception, and mucosal prolapse-like stenosis are causes in the early postoperative phase, with cancer recurrence in the late phase [2]. Surgery or endoscopic treatments (metal or pigtail stents, nasojejunal tube [NJT]) are methods of relieving obstruction, depending on the cause of ELS [2] [3] [4]. We describe a novel “endoloop and hemoclips” technique that successfully resolved ELS secondary to mucosal prolapse causing obstruction.
Abstract LB102: Effect of mistletoe extract on growth and proliferation of prostate cancer cells
Authors: Kavya Boyapati, Rajendra Kumar, Lillian Wilson, Yuhan Yang, Deven Topiwala, Keerti Soundappan, Eleni Panagopoulos, Ivelisse Page, Jennifer Durham, Michael Carducci, Channing Paller, Sushant Kachhap
Journal: Cancer Research (2021)

Abstract Complementary and alternative medicines are explored for their role in improving the quality of life of patients with cancer. Many anti-cancer drugs have been derived from natural sources. Mistletoe extract, composed of lectins, viscotoxins, flavonoids, and other biologically active substances, has two mechanisms of action: tumor cytotoxicity and immunomodulation. The cytotoxic effects of mistletoe extract are a result of protein synthesis interference, cell cycle inhibition, and apoptosis induction. Further, mistletoe extract has been shown to have anti-angiogenic properties. In Europe, Helixor M, mistletoe extract from Viscum album mali, is used as an anthroposophic medicine in the treatment of malignant and non-malignant tumors, malignant disorders with accompanying impairment of the hematopoietic organs, stimulation of bone marrow activity, reducing the risk of tumor recurrence, and diagnosed pre-cancerous disorders. However, only limited evaluation of mistletoe extract has been conducted in the United States. We studied the effects of Helixor M in prostate cancer. To evaluate its effect on cell proliferation and survival, we treated androgen receptor (AR) positive (LNCaP, LAPC4 and VCaP) and AR negative (PC3 and DU-145) cell lines with Helixor M. Our data indicates that LNCaP and LAPC4 cells were most sensitive to Helixor M while PC3, DU-145, and VCaP cells were relatively resistant to treatment. While AR protein levels and NF-kappaB subunits remained unaffected by treatment, there was an induction of apoptosis along with a concomitant decrease in LC3B, an autophagy marker, in all the sensitive prostate cancer cell lines. In search of pathways that may synergize with growth inhibition by Helixor M, we utilized CRISPR knockouts of TBK1, a kinase involved in autophagy induction, in LNCaP cells and tested whether TBK1 knockouts are synthetically lethal with Helixor M. Helixor M induced increased apoptosis in TBK1 knockouts as compared to parental LNCaP cells, indicating that TBK1 loss might be synthetically lethal with Helixor M. Citation Format: Kavya Boyapati, Rajendra Kumar, Lillian Wilson, Yuhan Yang, Deven Topiwala, Keerti Soundappan, Eleni Panagopoulos, Ivelisse Page, Jennifer Durham, Michael Carducci, Channing Paller, Sushant Kachhap. Effect of mistletoe extract on growth and proliferation of prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB102.
Prostate pathway embedded comparative trial: The ip3-prospect study
Authors: E.J. Bass, N. Klimowska-Nassar, E. Day, T. Sasikaran, F. Fransesca, M.R. Sydes, M. Winkler, N. Arumainayagam, B. Khoubehi, A. Pope, H. Sokhi, T. Dudderidge
Journal: European Urology (2021)
Laparoscopic colposacropexy: Technical considerations
Authors: M.C. Conde Redondo, F. Castrocviejo Royo, J. Diez, A. Alonso Villalba, E. Valsero, A. Ruano Mayo, A. Zamora Horcajadas, F. Natal Alvarez, J. Calleja Escudero
Journal: European Urology (2021)
Surgical efficiency of “one-lobe” technique vs. “three-lobe” technique for Holmium Laser Enucleation of the Prostate (HoLEP)
Authors: T. Westhofen, M. Schott, P.M.M. Keller, A.J. Tamalunas, M. Atzler, B. Ebner, C.G. Stief, G. Magistro
Journal: European Urology (2021)
Abstract 3045: Investigating the influence of glycosylation using cellular models of neuroblastoma
Authors: Meghan Cook, Alma Garcia, Katie Konieczny, Meghan Ferguson, Robert Campbell
Journal: Cancer Research (2021)

Abstract Background: Neuroblastoma is a common childhood malignancy with approximately 800 new cases diagnosed each year in the United States. Treatment of neuroblastoma directly depends on patient risk categories and includes combinations of surgery, radiation therapy, chemotherapy, stem cell therapy, immunotherapy, and retinoid therapy. Various characteristics of cancer in general and some specific to neuroblastoma cell lines contribute to a difficulty in delivering clinically relevant concentrations of therapeutic agents to neuroblastoma masses. Amplification of the MYCN gene in certain neuroblastoma cell lines correlates with increased cellular surface glycosylation levels as well as a worse prognosis for patients. Overexpression of the MUC1 gene is also associated with increased glycosylation, specifically type-O, in various cancers, but the role of MUC1 in neuroblastoma has not been thoroughly defined. The objective of this study was to evaluate the influence of type-O glycosylation on therapeutic uptake in different neuroblastoma cell lines. Methods: The neuroblastoma cell line SK-N-DZ, a MYCN-amplified line, was compared to SK-N-SH, a non-MYCN-amplified line (negative control) and BT-20, a highly glycosylated breast cancer cell line (positive control). Benzyl-α-GalNAc, an O-glycosylation inhibitor, was introduced to each cell line. To determine glycosylation levels in the respective cell lines, fluorescence assays were performed using CD227 (anti-MUC1) antibody. In vitro cytotoxicity assays were performed to determine maximum non-toxic concentrations of the glycosylation inhibitor (benzyl-α-GalNAc) and antibody (CD227) and to subsequently evaluate the functional role of glycosylation using cellular models of neuroblastoma. Results: The maximum non-toxic concentrations per 10,000 cells for each neuroblastoma cell line was 0.05 mg/ml of benzyl-α-GalNAc, and 6 µl of CD227 stock preparation. Preliminary results from fluorescence detection studies showed an increase in CD227-FITC antibody uptake by the MYCN-amplified neuroblastoma cells (SK-N-DZ) following exposure to the O-glycosylation inhibitor (benzyl-α-GalNAc). Cellular uptake of CD227-FITC by non-MYCN-amplified cell line (SK-N-SH) was less by comparison. Conclusion: Preliminary findings suggest that O-glycosylation is a barrier capable of limiting cellular uptake of agents in MYCN-amplified neuroblastoma cell lines. Ongoing studies are focused on investigating the influence of glycosylation inhibition on cytotoxicity of FDA-approved therapeutic agents. Citation Format: Meghan Cook, Alma Garcia, Katie Konieczny, Meghan Ferguson, Robert Campbell. Investigating the influence of glycosylation using cellular models of neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3045.
Abstract 1208: Identifying a novel glycolytic inhibitor for treatment of aggressive prostate cancer
Authors: Tanya Ivanova Stoyanova
Journal: Cancer Research (2021)

Abstract Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. Chalcones are a major class of widely occurring natural products that are intermediates in plant flavonoid isoflavonoid synthesis. They are characterized by an α,β-unsaturated carbonyl structure with two aromatic rings and commonly act as free-radical scavengers. Herein, we describe a chalcone derivative, SU086, as an anticancer agent for prostate cancer. Proteomic and metabolomic profiling demonstrate that SU086 impairs glycolysis, a critical pathway for cancer growth and survival. SU086 inhibited prostate cancer cell growth, migration, and invasion in vitro. Moreover, SU086 significantly delayed the tumor growth of cell line-derived xenograft models of CRPC as well as patient-derived xenografts (PDXs) in vivo, and the proliferation of primary human prostate cancer patient-derived tissues ex vivo. Furthermore, SU086 strongly synergized with standard of care second-generation anti-androgens, enzalutamide and abiraterone, in inhibiting prostate cancer cell growth in vitro and tumor growth in vivo. Our study identifies SU086 alone or in combination therapy settings as a novel treatment for aggressive prostate cancer. We demonstrate that SU086 represents a highly effective therapeutic strategy for both AR-sensitive and AR-insensitive prostate cancers and may potentially be applicable across multiple cancer types. Citation Format: Tanya Ivanova Stoyanova. Identifying a novel glycolytic inhibitor for treatment of aggressive prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1208.
Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC)
Authors: Pashalina Kehagias, Mohammad Krayem, Nadège Kindt, Ahmad Najem, Caroline Vandeputte, Fabrice Journé, Ahmad Awada, Ghanem E. Ghanem, Alain Hendlisz
Journal: Cancer Research (2021)

Abstract The introduction of the multi-targeted tyrosine kinase inhibitor (TKI) regorafenib in clinical routine improve patients' survival with metastatic CRC who failed to respond to standard therapies, however at the cost of significant toxicities. Moreover, patients' tumor exhibit heterogeneous responses and become resistant. Its mechanism of action remains largely unknown, challenging the selection of patients through the identification of clinically useful predictive biomarkers. This study aimed to explore the effects on human CRC cell lines of short- and long-term exposure to regorafenib and investigate resistance-related mechanisms. Two representative CRC cell lines were used, HCT-116 and SW480. Short-term (3 days) and long-term exposure to IC50 values (HCT-116, 3µM and 6µM; SW480, 5µM and 6µM respectively) were intended to explore intrinsic and acquired resistance. The observation of early morphological changes (increased cell volume) in SW480 cells after regorafenib exposure led us to investigate a drug-initiated senescence-like phenotype commonly associated with resistance to treatment allowing cell death escape. These cells acquired stable senescent-like properties (slow-cycling cells, high β-galactosidase activity) and the majority of them were arrested in the G2/M cell cycle phase after long treatment exposure. A specific senescence-associated secretome (high sIL6Rα in cell supernatants) was also observed. In contrast, HCT-116 cells exposed to regorafenib presented early senescent features (high β-galactosidase activity) but developed over time an acquired resistance triggering EMT (high migration activity, upregulation of EMT-related factors) also known to contribute to TKI resistance. Moreover, the investigation of MAPK and PI3K/AKT pathways pointed to the latter as a significant player in acquired resistance of HCT-116 cells (increase of AKT phosphorylation) possibly related to the presence of a PI3KCA mutation in this cell line. Our findings provide new insights into the phenotypic plasticity of CRC cells under treatment pressure able to (1) either acquire stable senescent-like properties or (2) use early senescence state to undergo EMT. Our findings need further investigations of the major determinants involved in regorafenib-induced phenotype-switching and may help to develop new therapeutic strategies to overcome related resistances. Citation Format: Pashalina Kehagias, Mohammad Krayem, Nadège Kindt, Ahmad Najem, Caroline Vandeputte, Fabrice Journé, Ahmad Awada, Ghanem E. Ghanem, Alain Hendlisz. Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1082.
Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study
Authors: Colin R Simpson, Chris Robertson, Eleftheria Vasileiou, Emily Moore, Colin McCowan, Utkarsh Agrawal, Helen R Stagg, Annemarie Docherty, Rachel Mulholland, Josephine L K Murray, Lewis D Ritchie, Jim McMenamin, Aziz Sheikh
Journal: The Lancet Digital Health (2021)
2型糖尿病(T2DM)におけるDoppler組織イメージング(TDI)により評価した左心室(LV)剛性に及ぼすシタグリプチンの影響
Authors: Sako Hideto, Miura Shinichiro, Furuyama Shodai, Matsunaga Akira, Saku Keijiro
Journal: Circulation (2013)
Intermediate-term overall survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non muscle-invasive bladder cancer in the Netherlands
Authors: F.J. Hinsenveld, J.L. Boormans, H.G. Van Der Poel, D.K.E. Van Der Schoot, A.N. Vis, K.K.H. Aben, T. Arends, J. De Rooij, W.A.K.M. Windt, K.T. Buddingh, S. Claus, K. Dekker, L.A. Grondhuis Palacios, T.J.N. Hermans, S. Van Huystee, M. Jaspers-Valentijn, A. Lenting, K.J. Lentjes, R.J.A. Oomen, M.A. Van Der Slot, P.J. Stelwagen, A. Van Der West, S.C. Van Beek
Journal: European Urology (2021)
A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinoma
Authors: Y. Shi, X. An, R. Yan, K. Yao, C. Xue, S. Guo, T. Liu, J. Li, H. Ma, L. Tian, F. Zhou, Y. Shi, H. Han
Journal: European Urology (2021)